We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

97 hedge funds and large institutions have $49.7M invested in Endocyte, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 23

9% less call options, than puts

Call options by funds: $193K | Put options by funds: $211K

5% less funds holding

Funds holding: 10297 (-5)

26% less capital invested

Capital invested by funds: $67.5M → $49.7M (-$17.8M)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

Holders
97
Holders Change
-5
Holders Change %
-4.9%
% of All Funds
2.58%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
28
Reduced
23
Closed
13
Calls
$193K
Puts
$211K
Net Calls
-$18K
Net Calls Change
-$12K
Name Holding Trade Value Shares
Change
Change in
Stake
Fiera Capital (Canada)
101
Fiera Capital (Canada)
Quebec, Canada
-$217K -54,053 Closed
TC
102
TFS Capital
Pennsylvania
-$138K -34,306 Closed
DekaBank Deutsche Girozentrale
103
DekaBank Deutsche Girozentrale
Germany
-$85K -21,200 Closed
Squarepoint
104
Squarepoint
New York
-$59K -14,600 Closed
Janney Montgomery Scott
105
Janney Montgomery Scott
Pennsylvania
-$43K -10,648 Closed
BNP Paribas Financial Markets
106
BNP Paribas Financial Markets
France
-$28.1K -7,006 Closed
TFA
107
Transamerica Financial Advisors
Florida
-$5K -1,000 Closed
US Bancorp
108
US Bancorp
Minnesota
-$2K -400 Closed
CCS
109
Crosspoint Capital Strategies
California
-$1K -210 Closed

ECYT Hedge Fund Activity: Q1 2016 in Review

97 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2016, worth a combined $49.7M — down 26% from $67.5M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ECYT and 9 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 28 added.

The largest buyer was Oxford Asset Management, adding an estimated $593K. The largest seller was Highland Capital Management (Texas), cutting an estimated $1.58M.

  • 97 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2016, down from 102 in Q4 2015.
  • Funds reported $49.7M of Endocyte, Inc. Common Stock stock for Q1 2016, down 26% quarter-over-quarter.
  • 9 funds opened new Endocyte, Inc. Common Stock positions in Q1 2016 and 13 closed out, a net change of -4 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q1 2016 was Oxford Asset Management, an estimated $593K added.
  • The largest Endocyte, Inc. Common Stock seller in Q1 2016 was Highland Capital Management (Texas), an estimated $1.58M sold.

Based on aggregated 13F filings for Q1 2016.